{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-006526","form_type":"8-K","ticker":"HOTH","cik":"0001711786","company_name":"Hoth Therapeutics, Inc.","filed_at":"2025-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.545214+00:00","generated_at":"2026-05-27T11:19:03.584509+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Hoth Therapeutics regains Nasdaq compliance on minimum bid price requirement","bullets":["Received Nasdaq notice on Jan 23, 2025 that stock closed at or above $1.00 for 10 consecutive business days (Jan 7-22, 2025).","Compliance with Nasdaq Listing Rule 5550(a)(2) achieved; delisting matter closed.","CEO Robb Knie said milestone reinforces commitment to long-term shareholder value.","Company continues advancing its biopharmaceutical pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-006526","json":"https://secwatch.observer/filing/0001213900-25-006526.json","markdown":"https://secwatch.observer/filing/0001213900-25-006526.md","text":"https://secwatch.observer/filing/0001213900-25-006526.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711786/000121390025006526/0001213900-25-006526-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711786/000121390025006526/ea0228609-8k_hoth.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T11:19:03.584509+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}